Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias:

Mechanism, Regulation, and Perspectives

C. Bezombes[1], J. J. Fournié[1] and G. Laurent[1,2]

Cancer Research Center of Toulouse

[1]INSERM UMR1037-CNRS ERL5294-Université Toulouse 3 BP3028, CHU Purpan, Toulouse, F-31300 France

[2]CHU Toulouse, Hôpital Purpan, Service Hématologie, Toulouse, F-31300 France

Phone: 33-5-62-74-45-62

Fax: 33-5-62-74-45-58

E-mail: christine.bezombes-cagnac@inserm.fr

Running title: Direct Effect of Rituximab

Keywords: Rituximab, cell signaling, B-cell malignancies

Word abstract: 164

Word count: 3965

Total number of tables: 2

Disclosures: The authors declare no conflict of interest.

Abstract

The anti-CD20 monoclonal antibody rituximab is the backbone of treatment for the B-cell malignancies non-Hodgkin's lymphoma and chronic lymphocytic leukemia. However, there is a wide variability in response to rituximab treatment and some patients are refractory to current standard therapies. Rituximab kills B cells by multiple mechanisms of action, including the immune-mediated mechanisms complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, as well as by direct effects on cell signaling pathways and cell membranes following CD20 binding. A large number of events affected by rituximab binding have been identified, including lipid raft modifications, kinase and caspase activation and effects on transcription factors and apoptotic/antiapoptotic molecules. Studies on cell lines and isolated tumor cells have shown that, by targeting these pathways, it may be possible to increase or decrease susceptibility to rituximab cell killing. Increased understanding of the direct effects of rituximab may therefore help to design new, rational combinations to improve the outcome of CD20-based therapy for patients who currently have suboptimal outcome following standard treatments.

Introduction

The anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in the last decade, improving overall survival and even cure rates in many of these malignancies (1). However, the clinical response to rituximab-based regimens can vary substantially, and some patients fail to respond to rituximab, even though they express CD20 on their malignant cells. This review considers the various different mechanisms of action of rituximab, and how patient and disease factors may impact on these, with a particular focus on the direct mechanisms of action and the multiple pathways that may contribute to variability of response. The article also addresses how combination with novel agents that target rituximab signaling pathways or their regulatory mechanisms might affect the clinical activity of the antibody.

Rituximab: Immune-mediated mechanisms of action

Rituximab kills B cells by multiple mechanisms that have been studied extensively *in vitro*. The most widely studied mechanisms are the immune-mediated mechanisms antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and the importance of these mechanisms is well established (2–4). While the relative contributions of these mechanisms to clinical efficacy remain unclear, *in vitro* studies have suggested ways in which the sensitivity of B cells to rituximab may be enhanced or reduced. For example, preclinical models show that expression of the complement-inhibitory cell surface proteins CD55 and CD59 by B cells can reduce rituximab cell killing (5, 6), while ADCC may be enhanced by agents such as bromohydrin (7) and lenalidomide (8, 9). However, lenalidomide has also been shown to downregulate CD20 and reduce ADCC *in vitro* (10). *In vivo*, the inhibitory FcγRIIb molecule has been shown to regulate ADCC, with mice deficient in this molecule showing enhanced ADCC in response to rituximab (2). In a study of the influence of the *FCGR3A* polymorphism in the FcγRIIIa receptor on the therapeutic response to rituximab, patients with a homozygous *FCGR3A*-158V genotype showed the best clinical response to rituximab. The FcγRIIIa receptor 158V allotype displays a higher affinity for rituximab and increased ADCC (3). CDC has also been shown to be crucial for rituximab therapeutic activity *in vivo* using a non-immunodeficient mouse model in which C1q and classical C activation was shown to be fundamental to the action of rituximab (4).

Rituximab: Direct cellular effects

Apart from the immune-mediated mechanisms CDC and ADCC, it has become increasingly clear that rituximab also targets B cells through direct mechanisms, which involve cell

membrane and intracellular signaling effects (11, 21). These mechanisms are induced by binding of rituximab to CD20 on the cell surface resulting in direct induction of cell death, inhibition of B-cell survival, and/or enhanced sensitivity to chemotherapeutic agents.

Effects of rituximab on lipids and rafts. Lipid components appear to play an important role in rituximab signaling through CD20. Binding of rituximab results in redistribution of CD20 to lipid microdomains or "rafts" in the membranes of cells from a Burkitt lymphoma cell line (11). Also, deletion analyses have identified a membrane-proximal sequence in the cytoplasmic carboxyl tail of CD20 as responsible for CD20 relocalization into rafts (12); this redistribution modifies raft stability and organization and modulates the associated signaling pathways (11). The clustering of CD20 into raft microdomains results in an apoptotic response mediated through an *src* kinase-dependent pathway (13). The integrity of lipid rafts and their association with CD20 and consequent activation of *src* kinases are all dependent on cholesterol, with cholesterol depletion inhibiting rituximab-induced apoptosis (14). We have reported in follicular lymphoma (FL) cell lines that rituximab inhibits B-cell receptor (BCR) signaling by preventing BCR relocalization into rafts and decreasing raft-associated cholesterol content (15).

CD20 translocation into rafts appears to be necessary for calcium mobilization and for rituximab-induced apoptosis in Burkitt lymphoma cell lines (16). However, it has also been demonstrated that anti-CD20 antibodies induce cell death through a caspase- and raft-independent mechanism (17), and a recent study showed that, at supersaturating doses, calcium release induced by rituximab (without crosslinking) is independent of both rafts and *src* kinases (18).

In the absence of crosslinking, rituximab binding to CD20 can also induce a rapid, transient increase in acid-sphingomyelinase activity and ceramide generation in raft microdomains in Burkitt and follicular lymphoma cell lines (19). The consequent increase in intracellular ceramide concentration can result, through PKCζ-mTOR module inhibition, in a decrease in growth and in survival (20).

Effects of rituximab on intracellular signaling pathways. Rituximab has been shown to exert its direct killing effects *in vitro* and *in vivo* through various intracellular signaling pathways via its F(ab')2 fragment (21). Multiple signaling pathways affected by rituximab binding to CD20 have been identified. These pathways include: activation or downregulation of protein kinases, phosphatases, caspases, and Bcl-2 family members; effects on transcription factors and gene expression; modulation of B-cell receptor signaling; and changes in the lipid distribution in the cell membrane (20, 22–31). The biologic effects of rituximab include: inhibition of cell survival and proliferation; induction of apoptosis and macroautophagy; and sensitization to

chemotherapeutic drugs and radiation. Table 1 lists the intracellular signaling pathways upon which rituximab has been shown to act.

Mechanisms of rituximab resistance

Immunotherapy with rituximab, alone or in combination with chemotherapy, has greatly improved treatment outcomes in patients with NHL and CLL. However, a subpopulation of patients will relapse and/or become unresponsive to rituximab. This suggests that some NHL cells may develop *in vivo* resistance to rituximab. Some of these mechanisms have been identified based on *in vitro* models, although for most of them, the *in vivo* relevance remains uncertain.

Regulation of rituximab direct effects

The signaling pathways that mediate the direct cellular effects of rituximab are regulated by a variety of intracellular and extracellular factors. This presents the possibility that perturbations in these regulatory mechanisms may affect the ability of rituximab to kill B cells, leading to resistance. Given the multiple pathways involved in rituximab signaling, targeting these pathways may offer the potential to overcome the mechanisms of resistance to rituximab that are observed *in vitro*, and possibly increase clinical efficacy in refractory or poorly responsive patients.

Lipids. As described above, rituximab activates the sphingomyelin cycle, and ceramide, the product of sphingomyelin degradation, acts as a secondary messenger for transducing growth inhibitory signals such as p27 accumulation. Theoretically, this complex cascade opens a large variety of regulation mechanisms, including the amount of sphingomyelin disposable for hydrolysis (in this case, the sphingomyelin fraction associated to the plasma membrane outer leaflet), the magnitude of the activation of the sphingomyelinase (in this case an acid not yet fully characterized), the correct enzyme routing for translocation, and the metabolism of ceramide (which may be metabolized in several ways). Very little is known about the influence of these parameters in NHL cell response to rituximab. However, it appears that the membrane lipid organization by itself indeed plays a role. Thus, the amount of GM1, a ganglioside and important sphingolipid constituent of lipid rafts, correlates with the susceptibility of NHL and CLL to rituximab *in vitro*, irrespective of the level of CD20 expression (32). GM1 may therefore represent a predictive factor for the response of lymphoma cells to rituximab (32). With the widespread use of cholesterol-lowering statins, which can interfere with the formation of cholesterol-rich lipid rafts (33), inhibit expression of GM1 (34), and also induce conformational

changes in CD20 *in vitro* (35), there has been some concern that patients treated with statins may have an impaired response to rituximab (36). However, recent clinical studies indicate that statin use in patients with NHL does not adversely affect the outcome following rituximab-based therapy (37–39).

Antiapoptotic proteins. As with many other antitumor agents, rituximab's direct effect is greatly influenced by a large variety of kinases and antiapoptotic proteins. For example, it has been described that antiapoptotic proteins such as Bcl-2 and Bcl-xL (themselves regulated by NF-κB) largely contribute to resistance to rituximab (40). Furthermore, silencing of Bfl-1, a transcriptional target of NF-κB, resulted in enhanced sensitivity to rituximab of diffuse large B-cell lymphoma (DLBCL) cells (41). However, most of these protective pathways are also targets for rituximab signaling. It is thus not surprising that the complete disappearance of these proteins also confers upon NHL cells a relative resistance to rituximab. For example, reduced expression of Bcl-2 family members, such as Bax and Bak, results in decreased direct killing by rituximab (42, 43). The dual effect of antiapoptotic protein expression level is well illustrated by Bcl-2 itself: the lack of this protein is a negative factor for clinical efficacy (44), whereas very high expression is protective.

The latter should be considered in the context of FL, with dramatic Bcl-2 accumulation due to the t(14;18) translocation being a molecular hallmark of FL cells. This molecular rationale has been exploited through Bcl-2 inhibitory agents as candidates for stimulating rituximab efficacy in Bcl-2-expressing NHL cells. Thus, the small molecule Bcl-2 inhibitor ABT-263 (navitoclax) has been shown to enhance the efficacy of rituximab in DLBCL tumor models (45, 46), while the BH3 mimetic AT-101 increased cell killing by rituximab plus cyclophosphamide in cell lines and animal models (47). The pan-bcl-2 inhibitor ABT-737 has also been shown to sensitize resistant B-cell lines to rituximab killing (48). The Bcl-2 antisense oligonucleotide oblimersen, as well as the small molecule Bcl-2 inhibitors navitoclax and obatoclax, are currently under evaluation in combination with rituximab in clinical trials in both NHL and CLL.

To conclude this section dealing with rituximab and apoptosis regulators, we should mention the intriguing observation made by Bonavida and coworkers, of increased expression of the apoptotic Fas molecule in NHL cells treated with rituximab (27). The authors showed that rituximab interferes with Fas expression at a transcriptional level through accumulation of the Yin Yang 1 (YY1) transcription factor, which binds to Fas gene regulatory sequences. In these cells, increased Fas expression correlated with increased Fas-induced apoptosis (27,28). This observation may have some consequences for the *in vivo* effect of rituximab. Indeed, Fas

accumulation on the membrane should facilitate NHL cell clearing by the immune system, notably by cytotoxic T cells present in FL tissue as previously documented (49). Moreover, Fas plays a role in the cellular response to cytotoxic drugs by transducing an apoptotic signal through death-inducing signaling complex (DISC) formation and caspase-8 activation (50). If Fas plays a role in the antitumor effect of rituximab, one can speculate that the loss of Fas at the cell surface or abnormal Fas signaling should contribute to rituximab resistance when used alone or in combination with drugs. In this perspective, it is interesting to note that, in NHL cells, the Fas gene may be mutated (51). Fas could not be the sole pro-apoptotic molecule involved in rituximab's mechanism of action. Indeed, rituximab cooperates with the rhApo2L/TRAIL, another death receptor, in NHL cell lines to promote apoptosis (30).

Phosphatidylinositol 3-kinase inhibitors. Phosphatidylinositol 3-kinase (PI3K) plays an important role in cell survival by regulating several enzymes, the most critical being Akt and its downstream targets, which include potent antiapoptotic proteins of the Bcl-2 family. Activation of PI3K in some cell lines results in loss of sensitivity to rituximab cell killing: in these cells, addition of a small molecule PI3K inhibitor can restore sensitivity to rituximab (51). Perifosine and CAL-101 are PI3K inhibitors in clinical development for hematologic malignancies. No information on their efficacy in combination with rituximab is available, but combination studies with rituximab and CAL-101 are currently underway.

Mammalian target of rapamycin inhibitors. Mammalian target of rapamycin (mTOR) is a serine–threonine kinase involved in cell growth signaling via cell surface receptors. We have previously shown that rituximab inhibits mTOR function (20). It is therefore conceivable that any mechanism that results in mTOR stimulation should render NHL cells resistant to rituximab. This hypothesis is a major concern since we have shown that, in biopsy specimens, FL cells display constitutive activation of the mTOR pathway. This pathway is highly sensitive to a variety of regulators acting both upstream of mTOR (MAPK, PI3K, TSC1, TSC2, etc.) and downstream (Pim kinases). All these proteins, including mTOR itself, are thus potential candidates for mediating resistance to rituximab. Targeting these proteins or (more directly) mTOR should improve the efficacy of rituximab efficacy. Thus, the mTOR inhibitor everolimus has been shown to have synergistic cell-killing activity with rituximab in mantle cell lymphoma and DLBCL cell lines (52, 53). A clinical trial is underway combining everolimus with rituximab in treatment of DLBCL.

Protein kinase C. The protein kinase C (PKC) family contains several isoforms, including the so-called "atypical" PKCζ enzyme. PKCζ is an important regulator of canonical pathways such as

NF-κB and MAPK, and through this signaling the enzyme promotes mitogenesis and survival. PKCζ is also the target of critical lipid messengers such as phosphatidic acid and ceramide. These are all reasons for considering this enzyme as an excellent target for antitumor therapy. In a previous paper we described how, in FL cells, rituximab decreased PKCζ activity and that PKCζ inhibition was responsible for the inhibition of a MAPK/mTOR module (20). Most interestingly, expression of constitutively active mutated forms of PKCζ confers significant protection of FL cells to rituximab (20). Thus, PKCζ expression or activity should be an indicator of rituximab activity. For the moment, the value of PKCζ as a biomarker is dampened by the lack of a specific antibody available for immunohistochemistry.

Other regulators. Other PKC isoforms or some tyrosine kinases are believed to interfere with rituximab activity. Therefore, agents targeting PKC (enzastaurin), *syk* kinase (fostamatinib), and *src* kinases (dasatinib) are all currently being evaluated in combination with rituximab in NHL and/or CLL. Fenretinide (4HPR) is a synthetic retinoid that has been shown to induce apoptosis in a variety of cancer cell lines, including human Burkitt lymphoma cell lines. In an *in vivo* model, concurrent administration of 4HPR and rituximab prevented disease progression in a minimal disease model and induced complete response in 80% of animals with established tumors (54). Similarly, combining lysophosphatidic acid acyltransferase-β (LPAAT-β) inhibitors with rituximab in NHL cell lines results in a twofold increase in apoptosis compared with either agent alone, and induced complete response in athymic mice bearing subcutaneous human Ramos lymphoma xenografts (55). Inhibition of survivin, a protein involved in inhibition of apoptosis and cell cycle regulation, using antisense oligonucleotides in combination with rituximab, has been shown to decrease viability of DoHH2 cells in culture compared with either agent alone. In a xenograft model, survivin inhibition in combination with rituximab significantly inhibited tumor growth compared with control cohorts (56).

Rituximab target availability

CD20 shaving. CD20 shaving is a phenomenon by which rituximab-CD20 complexes are removed from rituximab-opsonized B cells by monocytic cells in an FcγR-mediated reaction. This has been shown *in vitro* in mantle cell lymphoma and CLL cells using the THP-1 cell line or peripheral blood monocytes as the source of mononuclear cells (57). In CLL patients, the appearance of CD20-negative malignant B cells in the circulation has also been observed following single-agent rituximab, suggesting this shaving reaction may also occur *in vivo* (58). Shaving is believed to occur when the density of rituximab-opsonised malignant B cells in the circulation exceeds the capacity of the mononuclear-phagocytic system (59), and has not been reported in NHL, where relatively few malignant cells are seen in the circulation. Frequent

(thrice-weekly) low dosing of rituximab was shown to clear CLL cells from the peripheral blood without induction of shaving and/or the appearance of CD20-negative B cells (59). The relevance of shaving to clinical efficacy of rituximab in CLL, particularly in the context of immunochemotherapy, remains unclear.

Proteasomes. The ubiquitin-proteasome system may influence CD20 expression, which in turn influences sensitivity to rituximab. Therefore, the role of proteasomes in resistance to rituximab has been investigated by using lymphoma cell lines that have been rendered insensitive to rituximab. In these cells, proteasome inhibition indeed resulted in an increased expression of the carboxyl region of CD20 and subsequent partial restoration of sensitivity to rituximab (60). Similarly, the proteasome inhibitor bortezomib in combination with cytotoxic drugs may reverse insensitivity to rituximab (27). However, this issue remains controversial. Indeed, in other cellular models, inhibition of the ubiquitin-proteasome system actually resulted in downregulated CD20 and decreased sensitivity to rituximab, perhaps due to compensatory action by the lysosomal/autophagosomal system (61).

Alternatively spliced CD20 transcript. A truncated CD20 splice variant, called ΔCD20, has been detected in malignant or Epstein–Barr virus-transformed B cells but not in resting B lymphocytes isolated from healthy donors. In Raji and Ramos B-cell lines that were rendered insensitive to rituximab through repeated exposure to escalating doses of the drug, the expression of ΔCD20 increased with increasing rituximab exposure (62). There is some indication that increased expression of ΔCD20 is associated with lower expression of wild-type CD20, and that ΔCD20 is upregulated in patients with lowered response to rituximab (62). Manipulating the ratio of ΔCD20 to wild-type CD20 in malignant B cells could therefore be of benefit, but the factors regulating the expression of these two transcripts are currently unknown.

Controversial issues

Although our knowledge of the mechanism responsible for the direct antitumor effect of rituximab is increasing, several major concerns are still debated.

How does rituximab act in combination with chemotherapy?

This important question is still unresolved. It is possible that the direct effect of rituximab coincides with chemotherapy-induced DNA damage, through an additive, but mechanistically distinct, mechanism of action. Alternatively, some investigators have proposed that rituximab could act as a chemosensitizer. Previous studies from Bonavida's laboratory provide some

evidence that rituximab may indeed increase sensitivity to drugs by interfering with protective signaling pathways. For example, rituximab inhibits p38, MAPK, and NF-κB modules, resulting in the inhibition of the IL-10/IL-10 receptor autocrine/paracrine loop, downregulation of STAT3 activity, decreasing Bcl-2 expression, and subsequent sensitization to drug apoptosis (27). Rituximab has also been shown to upregulate Raf kinase inhibitor protein, thus decreasing the activity of the ERK1/2 pathway, reducing Bcl-xL expression, and subsequently increasing the sensitivity of NHL cells to chemotherapy (27).

Interestingly, rituximab has been implicated in sensitization of NHL cells to radiation-induced apoptosis through caspase-dependent and -independent mechanisms (31). Moreover, rituximab can also reverse P-glycoprotein-mediated multidrug resistance mediated by the induction of translocation of P-glycoprotein out of lipid rafts *in vitro* (63). However, the significance of these mechanisms in the clinical setting remains to be demonstrated. Moreover, any synergistic effects could be mediated by many other mechanisms. For example, it is possible that chemotherapy could improve antibody diffusion into tumors by reducing tumor size or priming NHL cells to direct rituximab apoptotic effects. One also cannot exclude the possibility that chemotherapy elicits an immune response by stimulating cellular effectors, which belong to adoptive or innate immunity and are able to recognize and eliminate rituximab-targeted cells. These questions should be of interest for optimizing the modalities of immunochemotherapy, with doses and timing of administration currently being somewhat empirical.

How can direct effects of anti-CD20 antibodies be increased?

All the data converge towards the notion that, although effective in patients, rituximab exerts a relatively modest direct inhibitory effect *in vitro* that can be counteracted by several potent signaling pathways. This observation explains why much more attention has been given to other mechanisms of action such as ADCC. However, some investigators have hypothesized that, by targeting other CD20 epitopes, it should be possible to elicit a more favorable cellular response, eventually leading to cell death. Thus, GA101, a type II, humanized, glycoengineered anti-CD20 antibody, has been rationally designed to build on the scientific platform created by rituximab. Specifically, the glycoengineering process has given GA101 strong affinity for the FcγRIIIa receptor, which in preclinical studies has been shown to result in significantly enhanced ADCC activity compared with rituximab (64). Similarly, it is thought that type II antibodies such as GA101 exhibit increased direct cell death rates compared with type I antibodies (65), due to their fundamentally different way of binding to CD20 (66). At present, the precise intracellular signaling pathways influenced by the binding of GA101 to CD20-positive cells remain to be fully determined, but very recently the mechanism of action has been described as non-apoptotic

lysosomal-dependent cell death (67). *In vitro*, GA101 appears to show higher antitumor activity against CD20-positive cells compared with rituximab (64, 67–70). Therefore, through its ability to bypass the apoptotic machinery, GA101 may help to eradicate tumors that are resistant to apoptosis and that respond poorly to chemotherapy or immunotherapy. In Phase I trials, GA101 has been shown to be well tolerated and active in patients with heavily pretreated, end-stage B-cell malignancies (66–73), and to induce rapid B-cell depletion and substantial tumor response in patients with relapsed-refractory CLL (74). Ongoing Phase III trials will confirm whether GA101 efficacy is improved versus current rituximab-based standards of care.

What should we look for in novel anti-CD20 antibodies?

One of the major challenges for antibody development is to create a screening system that has the simplicity of cell-line culture but also reasonably mimics the clinical situation, including the spatial 3D organization. The xenograft model has not been largely used in this context. The lack of a "spheroid" model for NHL is probably because, in contrast to carcinoma cells, NHL cells lack cadherin and thus cannot create cell-to-cell contacts. However, based on recent studies that have established that 3D spatial organization may interfere with intracellular signaling and antibody direct effects for trastuzumab (75), some sort of 3D model is required. Based on the trastuzumab experience, it appears that the direct antitumor effect of monoclonal antibodies may be underestimated unless explored in a 3D culture model. The main challenge for novel anti-CD20 antibodies, however, will be to demonstrate a clinical benefit over rituximab. Evidence of greater cell killing in preclinical studies is not meaningful without a demonstration of benefit in clinical trials. However, the bar is currently set high by rituximab, so large, well-designed trials with long follow-up would be required. In the shorter term, it may be possible to show a benefit, if it exists, in selected patient groups such as those in high-risk categories or those already refractory to rituximab.

Conclusions

It is clear that rituximab does exert a direct effect on NHL cells by activating a complex network of signaling pathways. However, these pathways are efficiently counter-regulated, resulting in a relatively limited antitumor activity by direct mechanisms. However, beyond these observations, the general concept that an anti-CD20 antibody may act as a more effective antitumor agent opens a large field of promising investigation to facilitate the direct effect of anti-CD20 antibodies. Among these different approaches, the most direct (and probably the most efficient) is to create new antibodies directed against different epitopes, capable of triggering potent negative signals converging in cell death. Thus, one can speculate that new anti-CD20

antibodies such as GA101 may not only challenge the first generation of anti-CD20 antibodies, but possibly even ultimately replace chemotherapy.

Acknowledgements

References

1. Keating GM. Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445–76.

2. Clynes R, Towers T, Presta L, et al. Inhibitory Fc receptors modulate *in vivo* cytoxicity against tumor targets. Nat Med 2000;6:443–6.

3. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754–8.

4. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab *in vivo*. J Immunol 2003;171:1581–7.

5. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab *in vitro*: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900–8.

6. Macor P, Tripodo C, Zorzet S, et al. *In vivo* targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556–63.

7. Gertner-Dardenne J, Bonnafous C, Bezombes C, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009;113:4875–84.

8. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650–7.

9. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma *in vitro* and *in vivo*. Am J Hematol 2009;84:553–9.

10. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180–9.

11. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003;63:534–40.

12. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998;161:3242–8.

13. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107:176–82.

14. Unruh TL, Li H, Mutch CM, et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology 2005;116:223–32.

15. Kheirallah S, Caron P, Gross E, et al. Rituximab inhibits B-cell receptor signaling. Blood 2010;115:985–94.

16. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139:439–46.

17. Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480–9.

18. Unruh TL, Zuccolo J, Beers SA, et al. Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcgamma receptors. J Immunother 2010;33:30–9.

19. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004;104:1166–73.

20. Leseux L, Laurent G, Laurent C, et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008;111:285–91.

21. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009;15:6582–94.

22. Eeva J, Nuutinen U, Ropponen A, et al. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in follicular lymphoma cells. Apoptosis 2009;14:687–98.

23. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673–83.

24. Daniels I, Turzanski J, Haynes A. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. Br J Haematol 2008;142:394–403.

25. Daniels I, Abulayham A, Thomson B, et al. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006;11:1013–23.

26. Turzanski J, Daniels I, Haynes A. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br J Haematol 2009;145:131–46.

27. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629–36.

28. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 2007;178:2287–95.

29. Vega MI, Baritaki S, Huerta-Yepez S, et al. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leuk Lymphoma 2011;52:108–21.

30. Daniel D, Yang B, Lawrence D, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007;110:4037–46.

31. Skvortsova I, Skvortsova S, Popper BA, et al. Rituximab enhances radiation triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res 2006;47:183–96.

32. Meyer zum Büschenfelde C, Feuerstacke Y, Götze KS, et al. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res 2008;68:5414–22.

33. Zhuang L, Kim J, Adam RM, et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959–68.

34. Blank N, Schiller M, Krienke S, et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 2007;179:3613–21.

35. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.

36. Rabinowitz I. Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5486.

37. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412–7.

38. Carver JR, Johnson T, Schuster SJ. Rituximab and statins. J Clin Oncol 2010;28:e611.

39. Samaras P, Heider H, Haile SR, et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010;89:783–7.

40. Jazirehi AR, Vega MI, Bonavida B, et al. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270–81.

41. Brien G, Trescol-Biemont M-C, Bonnefoy-Bérard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007;26: 5828–32.

42. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased *BAX* and *BAK* expression. Clin Cancer Res 2008;14:1550–60.

43. Dalle S, Dupire S, Brunet-Manquat S, et al. *In vivo* model of follicular lymphoma resistant to rituximab. Clin Cancer Res 2009;15:851–7.

44. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279–84.

45. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–8.

46. Ackler S, Mitten MJ, Foster K, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors *in vivo*. Cancer Chemother Pharmacol 2010;66:869–80.

47. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents *in vitro* and *in vivo* models of B-cell lymphoma. Blood 2008;111:5350–8.

48. Stolz C, Hess G, Hähnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008;112:3312–21.

49. Álvaro T, Lejeune M, Salvadó MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350–7.

50. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999;274:7987–92.

51. Scholl V, Stefanoff CG, Hassan R, Spector N, Renault IZ. Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:957–63.

52. Haritunians T, Mori A, O'Kelly J, et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007;21:333–9.

53. Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006;134:475–84.

54. Gopal A, Pagel J, Hedin N, et al. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004;103:3516–20.

55. Pagel J, Laugen C, Bonham L, et al. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-B and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res 2005;11:4857–66.

56. Ansell S, Arendt B, Grote D, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004;18:616–23.

57. Beum P, Kennedy A, Williams M, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600–9.

58. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280–8.

59. WiIliams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435–43.

60. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561–70.

61. Winiarska M, Bil J, Nowis D, et al. Proteolytic pathways involved in modulation of CD20 levels. Autophagy 2010;6:810–812.

62. Henry C, Deschamps M, Rohrlich P-S, et al. Identification of an alternative CD20 transcript variant in B cell malignancies coding for a novel protein associated to rituximab resistance. Blood 2010;115:2420–9.

63. Ghetie MA, Crank M, Kufert S, et al. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother 2006;29:536–44.

64. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B-cell cytotoxicity. Blood 2010;115:4393–402.

65. Cragg MS, Glennie MJ. Antibody specificity controls *in vivo* effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738–43.

66. Niederfellner GJ, Lammens A, Schwaiger M, et al. Crystal structure analysis reveals that the novel type II anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way. Blood 2009;114:Abstract 3726.

67. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117:4519–29.

68. Yang G, Hanzis C, Verselis S, et al. The anti-CD20 monoclonal antibody GA101 displays more robust anti-tumor activity versus rituximab in Waldenstrom's Macroglobulinemia (WM). Blood 2010;116:Abstract 4904.

69. Ysebaert L, Laprévotte E, Klein C, et al. Clinical and biological characteristics associated with in vitro activity of anti-CD20 monoclonal antibodies, rituximab and GA101, against chronic lymphocytic leukemia cells. Blood 2010;116:Abstract 2459.

70. Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10:178–85.

71. Sehn LH, Assouline SE, Stewart DA, et al. A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed/refractory cd20[+] malignant disease. Blood 2009;114:Abstract 934.

72. Salles G, Morschhauser F, Thiemblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL Patients – updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL). Blood 2010;116:Abstract 2868.

73. Cartron G, Thieblemont C, Solal-Céligny P, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL Patients – first results from a phase II study in patients with relapsed/refractory DLBCL and MCL. Blood 2010;116:Abstract 2878.

74. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114:Abstract 884.

75. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009;28:461–8.

Table 1. Rituximab effects on intracellular signaling pathways

Targeted pathway	Cell line model	Biologic effect	Reference
PKCζ/Raf/MEK/ERK/mTOR	FL cell lines	Inhibition of survival	(20)
A-SMase/CER/p27(Kip1)	FL and BL cell lines	Inhibition of proliferation	(19)
Caspase 3/9	FL cell lines	Apoptosis	(22)
CD20 relocalization in raft/calcium influx/caspases 3/7	BL cell lines		(16)
Src/calcium influx/caspases	NHL cell lines		(23)
Calcium influx	BL cell lines	CI-PCD	(24)
ΔΨm	BL cell lines		(25)
LC3II	BL cell lines	Macroautophagy	(26)
p38/SP1/IL10/STAT3/Bcl-2	BL cell lines	Chemosensitization	(27)
RKIP/Raf1/MEK/ERK/AP1/Bcl-xL	NHL cell lines		
RKIP/NIK/TAK/IKK/NF-κB/Bcl-xL	BL cell lines		
PI3K/PDK1/Akt/Bad/IKK/NF-κB/Bcl-xL	B-NHL cell lines		
Src/Raf1/MEK1/2/ERK1/2/ AP-1/ Bcl-xL	FL-NHL cell lines		
p38/MAPK/STAT3/NF-κB/ SP1/ Bcl-2	FL-NHL cell lines		
PI3K/Akt/NF-κB	B-NHL cell lines		
YY1, NF-κB, Bcl-xL	NHL cell lines		
p38 MAPK/NFκB/YY1/Fas	B-NHL cell lines	Sensitization to Fas	
Fas translocation in raft/DISC formation	BL cell lines	Sensitization to Fas	(28)
YY1	B-NHL cell lines	Sensitization to Apo2L/TRAIL	(29)
Caspase 3/7	NHL cell lines and xenograft	Sensitization to Apo2L/TRAIL	(30)
Survivin/AIF/XIAP/Hsp70	FL and BL cell lines	Sensitization to radiation	(31)

AIF, apoptosis-inducing factor; A-SMase, acid-sphingomyelinase; BL, Burkitt lymphoma; B-NHL, B-cell non-Hodgkin's lymphoma; CER, ceramide; CI-PCD, caspase-independent programmed cell death; DISC, death-inducing signaling complex; FL, follicular lymphoma; IKK, inhibitor of nuclear factor κβ kinase; IL10, Interleukin-10 protein; LC3II, light chain 3-II protein; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NHL, non-Hodgkin's lymphoma; NIK, NFκB inducing kinase; PDK1, pyruvate dehydrogenase kinase 1; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; RKIP, Raf kinase inhibitory protein; SP1, specific protein 1; STAT3, signal transducer and activator of transcription 3 factor; TAK, transforming growth factor β activated kinase; TRAIL, TNF-related apoptosis-inducing ligand; XIAP, x-linked inhibitor of apoptosis protein; YY1, Yin Yang 1.

Table 2. Experimental combination therapies with rituximab to address rituximab resistance and sensitivity

Agent	Mechanism	Therapeutic partners	Patient population	Clinical trial registry number*
Oblimersen	Bcl-2 antisense oligonucleotide	Rituximab, fludarabine	CLL	NCT00078234
		Rituximab	NHL	NCT00054639
Navitoclax	Small molecule Bcl-2 inhibitor	Fludarabine, cyclophosphamide, rituximab Bendamustine, rituximab	CLL	NCT00868413
		Rituximab	CD20-positive lymphoid malignancies	NCT00788684
		Dose-intense rituximab	CLL	NCT01087151
Obatoclax	Small molecule Bcl-2 inhibitor	Fludarabine, rituximab	CLL	NCT00612612
		Rituximab, bendamustine	NHL	NCT01238146
		Rituximab	FL	NCT00427856
CAL-101	PI3K inhibitor	Rituximab	CLL or SLL	NCT01203930
		Rituximab, bendamustine, ofatumumab, fludarabine	NHL or CLL	NCT01088048
Everolimus	mTOR inhibitor	Rituximab	DLBCL	NCT00869999
		Rituximab, chemotherapy	DLBCL	NCT01334502
Enzastaurin	Protein kinase C inhibitor	R-CHOP	DLBCL	NCT00451178
		R-GEMOX	DLBCL	NCT00436280
Dasatinib	BCR/ABL and Src family tyrosine kinase inhibitor	Rituximab	CLL	NCT00949988
		Rituximab, fludarabine	CLL or SLL	NCT01173769

ABL, Abelson protein; BCR, breakpoint cluster region protein; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; mTOR, mammalian target of rapamycin; NHL, non-Hodgkin's lymphoma; PI3K, phosphatidylinositol 3-kinase; SLL, small lymphocytic leukemia.

*www.clinicaltrials.gov

AACR American Association for Cancer Research

Molecular Cancer Research

Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives

Christine Bezombes, Jean-Jacques Fournié and Guy Laurent

Updated version	Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-11-0154
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://mcr.aacrjournals.org/content/early/2011/09/15/1541-7786.MCR-11-0154. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.